Technical Analysis for FUM - Futura Medical Plc
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Outside Day | Range Expansion | 0.00% | |
Gapped Up | Strength | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Calm After Storm | Range Contraction | 0.42% | |
NR7 | Range Contraction | 0.42% | |
Narrow Range Bar | Range Contraction | 0.42% | |
Gapped Down | Weakness | 0.42% | |
Golden Cross | Bullish | -2.33% | |
Calm After Storm | Range Contraction | -2.33% | |
Narrow Range Bar | Range Contraction | -2.33% |
Alert | Time |
---|---|
Fell Below Previous Day's Low | 1 day ago |
Down 3% | 1 day ago |
Down 2% | 1 day ago |
Down 1% | 1 day ago |
Lower Bollinger Band Support | 1 day ago |
Free Daily (Stock) Chart Reading
Futura Medical Plc Description
Futura Medical plc is a United Kingdom-based pharmaceutical company that develops products for consumer healthcare. The Company is engaged in the research and development of pharmaceutical drugs and medical devices and the commercial exploitation. It is also engaged in transdermal delivery and has developed a transdermal technology, DermaSys for the absorption of active molecules through the skin. It specializes in sexual health and pain relief, and has approximately five products in its development pipeline, which include CSD500, MED2002, TPR100, TIB200 and SPR300. Its CSD500 product incorporates an erectogenic gel (known as Zanifil gel) to help men maintain a firmer erection during intercourse whilst wearing a condom. Its MED2002 is a gel applied directly to the penis for the treatment of male erectile dysfunction (ED). The Company's TPR100 is a gel to provide pain relief. Its SPR300 is a gel, which combines methyl salicylate and menthol with the DermaSys delivery system.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Health Healthcare Consumer Pain Pharmaceutical Medicine Pipe Drugs Skin Medical Device Pharmacology Analgesics Consumer Healthcare Dosage Forms Erectile Dysfunction Gabaa Receptor Positive Allosteric Modulators Pharmaceutical Drugs Sexual Health
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 67.0 |
52 Week Low | 23.2816 |
Average Volume | 822,101 |
200-Day Moving Average | 39.87 |
50-Day Moving Average | 40.18 |
20-Day Moving Average | 38.11 |
10-Day Moving Average | 37.17 |
Average True Range | 2.14 |
RSI (14) | 40.48 |
ADX | 18.99 |
+DI | 14.58 |
-DI | 29.01 |
Chandelier Exit (Long, 3 ATRs) | 37.37 |
Chandelier Exit (Short, 3 ATRs) | 39.64 |
Upper Bollinger Bands | 42.04 |
Lower Bollinger Band | 34.18 |
Percent B (%b) | 0.19 |
BandWidth | 20.63 |
MACD Line | -1.04 |
MACD Signal Line | -0.66 |
MACD Histogram | -0.3736 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 39.33 | ||||
Resistance 3 (R3) | 39.20 | 37.85 | 38.71 | ||
Resistance 2 (R2) | 37.85 | 36.91 | 37.91 | 38.51 | |
Resistance 1 (R1) | 36.75 | 36.34 | 36.08 | 36.88 | 38.30 |
Pivot Point | 35.40 | 35.40 | 35.06 | 35.46 | 35.40 |
Support 1 (S1) | 34.30 | 34.46 | 33.63 | 34.43 | 33.00 |
Support 2 (S2) | 32.95 | 33.89 | 33.01 | 32.79 | |
Support 3 (S3) | 31.85 | 32.95 | 32.59 | ||
Support 4 (S4) | 31.98 |